JUVEDERM ULTRA PLUS PP
Generic Name and Formulations:
Hyaluronic acid 24mg/mL; injectable gel implant.
Indications for JUVEDERM ULTRA PLUS:
Correction of moderate-to-severe facial wrinkles and folds (eg, nasolabial folds).
See full labeling. Inject slowly with least amount of pressure necessary. May use supplementary anesthesia during and post-inj. ≥18yrs: Individualize. Initial treatment: usually 1.6mL per site; repeat treatment: usually 0.7mL per site. Max limit: 20mL/60kg per year. May require touch-up treatments after 1–2 weeks to achieve desired effects.
<18yrs: not established.
History of anaphylaxis or presence of multiple severe allergies. Allergies to Gram (+) bacterial proteins.
Should only be used by trained and experienced healthcare practitioners. Obtain patient's complete medical history prior to initiation. Avoid intravascular inj; discontinue immediately if changes in vision, signs of stroke, blanching of skin or unusual pain during or shortly after procedure occurs. Risk of infection. Defer if active inflammatory process or infection is present at specific sites. Use in non-lip or non-perioral areas: not established. Possible risk of an inflammatory reaction at implant site if laser treatment, chemical peeling, or any other procedure based on active dermal response is considered after Juvederm Ultra/Ultra Plus or if product is given before skin has healed completely after such a procedure. Known susceptibility to keloid formation, hypertrophic scarring, and pigmentation disorders: not studied. Advise patients to avoid strenuous exercise, extensive sun or heat, and alcoholic beverages within first 24hrs. Pregnancy, nursing mothers: not established.
Caution with concomitant immunosuppressants. Increased bruising or bleeding at inj sites with concomitant aspirin, NSAIDs, warfarin.
Inj site reactions (eg, swelling, tenderness, firmness, bruising, lumps/bumps, redness, pain, discoloration, itching); rare: vision impairment, blindness, cerebral ischemia/hemorrhage, stroke, skin necrosis, facial structure damage.
Single-use syringe—1 (w. needles)
Sign Up for Free e-newsletters
- Triplet Regimen Found Most Effective for Relapsed/Refractory Multiple Myeloma
- Integrating Preoperative Oral Care Into Cancer Treatment Plans
- Current Status and Dilemma of Second-line Treatment in Advanced Pancreatic Cancer: Is There a Silver Lining?
- American Association for Cancer Research Releases Its 2018 Annual Report
- Pulmonary Toxicity Increased in Pediatric Hodgkin Lymphoma Treated With Brentuximab Vedotin
- Benefit of Chemotherapy for Breast Cancer Observed With Midrange Gene Assay Score
- Antioxidant Interaction With Cancer Therapy
- Young Survivors of Breast Cancer Report Sexual Quality of Life Declines After Treatment
- Myeloablative Conditioning Effective in AML Secondary to MDS/MPN Prior to Allogeneic HCT
- Insurance Status Influences Overall Survival in Follicular Lymphoma
- Skin Cancer Screening: Are They Effective?
- Metronidazole, Vancomycin Recommended for C Difficile in Pediatric Oncology, HSCT
- CDC: HPV Vaccination Rates on the Rise Among Adolescents
- High-Dose vs Standard-Dose Flu Vaccine in Elderly Receiving Chemotherapy
- FDA Grants Approval to Novel Treatment for Hairy Cell Leukemia
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|